A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone
(MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day
cycles.